Bank Pictet & Cie Europe AG Purchases 15,004 Shares of Edwards Lifesciences Corporation $EW

Key Points

• Bank Pictet & Cie Europe AG significantly increased its investment in Edwards Lifesciences Corporation by 254.2%, acquiring 15,004 additional shares to bring its total holdings to 20,906 shares, valued at approximately $1.635 million.
• Multiple analysts have upgraded Edwards Lifesciences' stock prices recently, with target prices ranging from $82.00 to $95.00 and a consensus rating of "Moderate Buy".
• Edwards Lifesciences reported strong financial results, with earnings per share of $0.67 for the most recent quarter, surpassing analyst expectations and indicating an 11.9% increase in revenue year-over-year.

Bank Pictet & Cie Europe AG increased its position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 254.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 20,906 shares of the medical research company's stock after acquiring an additional 15,004 shares during the quarter. Bank Pictet & Cie Europe AG's holdings in Edwards Lifesciences were worth $1,635,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of EW. Quantbot Technologies LP purchased a new position in Edwards Lifesciences in the first quarter worth $26,000. SouthState Corp purchased a new stake in Edwards Lifesciences in the first quarter valued at about $27,000. Global X Japan Co. Ltd. boosted its holdings in Edwards Lifesciences by 116.1% in the first quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock worth $29,000 after acquiring an additional 216 shares in the last quarter. Tradewinds Capital Management LLC grew its stake in shares of Edwards Lifesciences by 102.5% during the first quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company's stock worth $29,000 after acquiring an additional 205 shares during the last quarter. Finally, Rossby Financial LCC purchased a new position in shares of Edwards Lifesciences in the 1st quarter valued at approximately $29,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. Mizuho boosted their target price on shares of Edwards Lifesciences from $87.00 to $95.00 and gave the stock an "outperform" rating in a research report on Friday, July 25th. Truist Financial boosted their price objective on shares of Edwards Lifesciences from $81.00 to $82.00 and gave the company a "hold" rating in a report on Friday, July 25th. Piper Sandler raised their target price on Edwards Lifesciences from $83.00 to $90.00 and gave the stock an "overweight" rating in a research note on Friday, July 25th. Royal Bank Of Canada lifted their price target on Edwards Lifesciences from $85.00 to $89.00 and gave the stock an "outperform" rating in a research report on Friday, July 25th. Finally, Stifel Nicolaus set a $85.00 price objective on Edwards Lifesciences and gave the company a "buy" rating in a report on Monday. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Edwards Lifesciences presently has an average rating of "Moderate Buy" and a consensus price target of $86.61.

Edwards Lifesciences Stock Performance

NYSE EW opened at $75.35 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. The stock's fifty day moving average is $78.50 and its two-hundred day moving average is $75.62. The firm has a market capitalization of $44.24 billion, a P/E ratio of 10.84, a price-to-earnings-growth ratio of 3.59 and a beta of 1.07. Edwards Lifesciences Corporation has a fifty-two week low of $64.00 and a fifty-two week high of $83.00.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.05. The firm had revenue of $1.53 billion during the quarter, compared to analysts' expectations of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. Edwards Lifesciences's revenue was up 11.9% compared to the same quarter last year. During the same period last year, the business earned $0.70 earnings per share. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Larry L. Wood sold 8,950 shares of the stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the transaction, the insider directly owned 206,900 shares in the company, valued at approximately $16,150,614. This represents a 4.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Daniel J. Lippis sold 4,114 shares of the firm's stock in a transaction on Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the sale, the vice president directly owned 22,002 shares of the company's stock, valued at approximately $1,748,278.92. This trade represents a 15.75% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.29% of the company's stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.